Search Results for: LYN

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Respiratory syncytial virus (RSV) attachment and entry
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Poziotinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Mobocertinib
  • Almonertinib
  • Amivantamab
  • Laryngeal cancer
  • Cervical cancer
  • Oral cancer
  • Gastric cancer
  • Choriocarcinoma
  • Esophageal cancer
  • Glioma
  • Bladder cancer
Novel EPOR erythropoietin receptor
  • Signaling by Erythropoietin
  • Signaling by Erythropoietin
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Darbepoetin alfa
  • Erythropoietin
  • Dibromotyrosine
  • Peginesatide
  • Methoxy polyethylene glycol-epoetin beta
  • Congenital polycythemia; Familial erythrocytosis (ECYT)
Novel ERBB3 erb-b2 receptor tyrosine kinase 3
  • Tucatinib
  • Type I diabetes mellitus
  • Lethal congenital contractural syndrome (LCCS)
Novel ERBB4 erb-b2 receptor tyrosine kinase 4
  • Afatinib
  • Fostamatinib
  • Brigatinib
  • Zanubrutinib
Novel EVL Enah/Vasp-like
  • Generation of second messenger molecules
  • Signaling by ROBO receptors
  • Signaling by ROBO receptors
  • RHO GTPases Activate Formins
Novel FASLG Fas ligand
  • Caspase activation via Death Receptors in the presence of ligand
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • Interleukin-4 and Interleukin-13 signaling
  • Dimerization of procaspase-8
  • FasL/ CD95L signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • FOXO-mediated transcription of cell death genes
  • TNFs bind their physiological receptors
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
Novel FCAR Fc alpha receptor
  • Neutrophil degranulation
Novel FCER1G Fc epsilon receptor Ig
  • GPVI-mediated activation cascade
  • Cell surface interactions at the vascular wall
  • Fc epsilon receptor (FCERI) signaling
  • Fc epsilon receptor (FCERI) signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated NF-kB activation
  • Dectin-2 family
  • Dectin-2 family
  • Neutrophil degranulation
  • Platelet Adhesion to exposed collagen
  • Benzylpenicilloyl polylysine
Novel FCGR2A Fc gamma receptor IIa
  • FCGR activation
  • FCGR activation
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of phospholipids in phagocytosis
  • Neutrophil degranulation
  • FCGR3A-mediated IL10 synthesis
  • Cetuximab
  • Etanercept
  • Human immunoglobulin G
  • Abciximab
  • Alemtuzumab
  • Daclizumab
  • Bevacizumab
  • Catumaxomab
  • Sarilumab
  • Systemic lupus erythematosus
Novel FCGR2B Fc gamma receptor IIb
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Etanercept
  • Human immunoglobulin G
  • Abciximab
  • Tositumomab
  • Alemtuzumab
  • Antithymocyte immunoglobulin (rabbit)
  • Palivizumab
  • Daclizumab
  • Bevacizumab
  • Sarilumab
  • Systemic lupus erythematosus
Novel FOLR1 folate receptor alpha
  • COPII-mediated vesicle transport
  • Cargo concentration in the ER
  • COPI-mediated anterograde transport
  • Folic acid
  • Vintafolide
  • Farletuzumab
  • Mirvetuximab soravtansine
  • Pafolacianine
Novel GAB2 GRB2 associated binding protein 2
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Interleukin-15 signaling
  • Interleukin receptor SHC signaling
  • FLT3 Signaling
  • FLT3 Signaling
  • STAT5 Activation
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
Novel GAB3 GRB2 associated binding protein 3
  • Signaling by CSF1 (M-CSF) in myeloid cells
Novel GP6 glycoprotein VI platelet
  • GPVI-mediated activation cascade
  • Cell surface interactions at the vascular wall
  • Platelet Adhesion to exposed collagen
Novel GRIA3 glutamate ionotropic receptor AMPA type subunit 3
  • Activation of AMPA receptors
  • Trafficking of AMPA receptors
  • Trafficking of GluR2-containing AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Synaptic adhesion-like molecules
  • Glutamic acid
  • Butabarbital
  • Ethanol
  • Lithium cation
  • Aniracetam
  • Talampanel
  • CX-717
  • Fluciclovine (18F)
  • Lithium citrate
  • Lithium succinate
  • Lithium carbonate
  • Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
Novel HCLS1 hematopoietic cell-specific Lyn substrate 1
Novel HNRNPK heterogeneous nuclear ribonucleoprotein K
  • SUMOylation of RNA binding proteins
  • mRNA Splicing - Major Pathway
  • Processing of Capped Intron-Containing Pre-mRNA
  • HCMV Late Events
  • Artenimol
  • Phenethyl Isothiocyanate
Novel IGHA1 immunoglobulin heavy constant alpha 1
Novel IL1B interleukin 1 beta
  • Interleukin-1 processing
  • Pyroptosis
  • CLEC7A/inflammasome pathway
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-1 signaling
  • Purinergic signaling in leishmaniasis infection
  • CASP4-mediated substrate cleavage
  • CASP5-mediated substrate cleavage
  • Donepezil
  • Minocycline
  • VP025
  • Gallium nitrate
  • Talmapimod
  • Etiprednol dicloacetate
  • VX-702
  • VX-765
  • Andrographolide
  • Canakinumab
  • Rilonacept
  • Foreskin keratinocyte (neonatal)
  • Binimetinib
  • Gevokizumab
  • Dilmapimod
Novel IL2RB interleukin 2 receptor subunit beta
  • RAF/MAP kinase cascade
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-2 signaling
  • Interleukin receptor SHC signaling
  • Denileukin diftitox
  • Aldesleukin
  • Basiliximab
  • Daclizumab

Page 3 out of 14 pages